TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

A new Alzheimer’s drug, lecanemab, may slow disease progression and offer patients up to four extra years of stable health.

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

Lecanemab's price may pose another barrier, even with insurance coverage. The drug's maker, Eisai, expects the medicine alone to cost $26,500 a year. Diagnostic and follow-up tests will add to that.

Lecanemab, the new Alzheimer’s drug approved by the FDA, explained Lecanemab doesn’t cure Alzheimer’s disease. Patients will still decline — but not as quickly.

In a large study, experimental drug lecanemab was able to slow down Alzheimer's, but not stop it. Some researchers think the drug will become the first to help many patients; others have questions.

Lecanemab and Aduhelm are part of a class of drugs called monoclonal antibodies, and the agency that oversees Medicare has said it will only pay for this type of Alzheimer’s drug for patients ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...